Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Olympus (7733 JP): Medical Business Is on a Strong Foothold; Buy at Current Level

Olympus (7733 JP) Q4FY22: Net Profit More Than Doubled; Record High Profit Projection for FY23

Olympus Corp (7733 JP): Started FY23 on a Strong Note Thanks to Favorable Foreign Exchange Rate

Olympus: Recovery of Endoscopic Business and Sale of Imaging Business to Support Earnings Growth

Hoya 3Q Results: Earnings Beat Consensus and Point to Recovery Ahead

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Apple: 1Q FY09/21 Earnings Set New All-Time Records

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Bottom-Up

<a href="https://www.smartkarma.com/entities/olympus-corp" target="_blank" data-smartkarma-citation="entities:356:1" rel="noopener">Olympus Corp (7733 JP)</a>  reported its 3QFY03/2021 results on Friday (12th February) after market which saw revenues and operating profit increasing on a YoY basis, after seeing declines during the last three quarters due to the Covid-19 pandemic.During 2QFY03/21, the company’s revenues grew 2.1% YoY while OP increased by 19.3% YoY. The reported revenues beat consensus estimates by 6.4%, and the OP for the quarter beat consensus estimates by a massive 68%. The strong earnings for the quarter were driven by Olympus’ mainstay Endoscopic Solutions Division (ESD) which helped offset minor declines in revenue from other two segments.All three segments have seen strong recovery in revenues during the last quarter of 2020.<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/188/423/original/image_62209000621613158008996.png?1613158012" class="editor-image img-responsive" data-smartkarma-image-id="188423"></figure><div class="content-caption">Source: Company Disclosures, January to December 2020</div>We discuss the details below.

Olympus Corp (7733 JP)  reported its 3QFY03/2021 results on Friday (12th February) after market which saw revenues and operating profit increasing on a YoY basis, after seeing declines during the last three quarters due to the Covid-19 pandemic.During 2QFY03/21, the company’s revenues grew 2.1% YoY while OP increased by 19.3% YoY. The reported revenues beat consensus estimates by 6.4%, and the OP for the quarter beat consensus estimates by a massive 68%. The strong earnings for the quarter were driven by Olympus’ mainstay Endoscopic Solutions Division (ESD) which helped offset minor declines in revenue from other two segments.All three segments have seen strong recovery in revenues during the last quarter of 2020.Source: Company Disclosures, January to December 2020We discuss the details below.

Olympus 3Q Earnings Beat Consensus; Upward Revision to Full-Year Guidance